12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Incivek regulatory update

Vertex said in its 4Q12 earnings that it submitted an sNDA to FDA and a supplemental NDS to Health Canada for a twice-daily dosing regimen of Incivek telaprevir to treat chronic HCV infection. The small molecule HCV...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >